HighTower Advisors
AXSM icon

HighTower Advisors’s Axsome Therapeutics AXSM Stock Holding History

HighTower Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-200
Closed -$1.25K – 3771
2025
Q1 		$1.25K Buy
+200
New +$22.8K ﹤0.01% 3644

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HighTower Advisors's AXSM Position: Q1 2026 in Review

HighTower Advisors increased its Axsome Therapeutics (AXSM) stake by 1.2% in Q1 2026, buying an estimated $114K and bringing the position to 56,633 shares worth $9.57M. The position accounts for 0.01% of the portfolio, ranked #901.

HighTower Advisors first reported a position in AXSM in Q4 2022 and has held it in 8 quarters since. The position peaked at $10.2M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • HighTower Advisors held 56,633 shares of Axsome Therapeutics worth $9.57M as of Q1 2026.
  • HighTower Advisors bought 661 Axsome Therapeutics shares in Q1 2026, an estimated $114K.
  • Axsome Therapeutics made up 0.01% of HighTower Advisors's portfolio in Q1 2026, its #901 holding.
  • HighTower Advisors first reported a position in Axsome Therapeutics in Q4 2022 and has held it in 8 quarters since.
  • HighTower Advisors's Axsome Therapeutics position peaked at $10.2M in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.